# REDOSE (NCT03927391)

> Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03927391
- Phase: PHASE4
- Status: COMPLETED
- Sponsor: Radboud University Medical Center
- Conditions: Prostatic Neoplasms, Castration-Resistant
- Interventions: Enzalutamide
- Enrollment: 57
- Primary outcome: To determine the change in the CNS side effect fatigue* in frail (m)CRPC patients treated with a reduced dose of enzalutamide (120mg OD) compared to the standard dose of enzalutamide (160mg OD) after 6 weeks of treatment.

## Commentary we found

- Podcasts: 14
- YouTube: 8
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=redose-nct03927391

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03927391", "email": "<work email>"}; the inbox owner confirms by the emailed link.